AdaptHealth Corp. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers AdaptHealth Corp.'s (AHCO) Annual Report on Form 10-K for the fiscal year ended December 31, 2025. AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions, including home medical equipment (HME), medical supplies, and related services. The company operates through four reportable segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. As of year-end 2025, the company serviced approximately 4.3 million patients annually across 640 locations in 48 states.
Key Financial Metrics
| Metric | 2025 (in millions) | 2024 (in millions) | Change |
|---|---|---|---|
| Net Revenue | $3,244.9 | $3,261.0 | (0.5)% |
| Operating Income | $90.9 | $263.7 | (65.5)% |
| Net Loss Attributable to AdaptHealth | $(70.8) | $90.4 (Income) | Turned to Loss |
| Adjusted EBITDA | $616.7 | $688.7 | (10.5)% |
| Adjusted EBITDA Margin | 19.0% | 21.1% | (2.1) pts |
| Free Cash Flow | $219.4 | $235.8 | (7.0)% |
| Total Debt (Principal) | $1,750.0 | $2,000.0 | Reduced |
| Cash and Equivalents | $106.1 | $109.7 | (3.3)% |
Note: The company recorded a non-cash goodwill impairment charge of $128.0 million in 2025, primarily related to the Diabetes Health segment.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased slightly by 0.5% to $3.24 billion. This was driven by a $92.4 million reduction due to dispositions (primarily incontinence and infusion businesses in the Wellness at Home segment), partially offset by $56.9 million in organic revenue growth and $19.5 million from acquisitions.
- Profitability Impact: Operating income fell 65.5% to $90.9 million, and the company reported a net loss of $70.8 million compared to net income of $90.4 million in 2024. The decline was significantly impacted by the $128.0 million goodwill impairment charge and increased general and administrative expenses (up 6.4%) due to legal settlement costs and equity-based compensation.
- Segment Performance:
- Sleep Health: Revenue increased 2.1% to $1.38 billion; Adjusted EBITDA decreased 10.9% due to higher costs.
- Respiratory Health: Revenue increased 6.1% to $691.2 million; Adjusted EBITDA increased 4.8%.
- Diabetes Health: Revenue decreased 3.6% to $592.4 million due to a shift in payor mix; Adjusted EBITDA dropped 56.9% to $26.1 million.
- Wellness at Home: Revenue decreased 9.8% to $583.1 million, largely due to business dispositions.
- Debt Reduction: The company voluntarily repaid $218.8 million on its term loan during 2025. Total debt principal decreased from $2.0 billion to $1.75 billion.
Guidance, Outlook, Risks, and Unusual Items
- Regulatory Risks (OBBBA): The "One Big Beautiful Bill Act" (OBBBA), signed July 4, 2025, introduces significant changes to Medicaid eligibility and financing. While many provisions take effect in 2027, the company notes potential adverse effects on reimbursement levels and beneficiary counts. The act also reduced the company's 2025 estimated cash income tax liability, creating a $29.2 million tax receivable.
- Goodwill Impairment: A $128.0 million non-cash impairment was recognized for the Diabetes Health reporting unit. The Wellness at Home and Respiratory Health units showed fair value excesses of less than 10% and 20%, respectively, indicating vulnerability to future impairments.
- Legal Proceedings:
- Securities Litigation: A proposed settlement of $35.0 million ($34.0 million from insurance, $1.0 million from the company) was reached regarding a class action alleging false statements about billing practices and compliance. Preliminary court approval was granted in February 2026.
- False Claims Act (FCA): The company is cooperating with two ongoing civil investigations by U.S. Attorney's Offices regarding billing for humidifiers (since 2017) and respiratory devices (since 2018).
- Class Action Settlement: A proposed $14.5 million settlement was reached regarding a North Carolina debt collection practices class action.
- Internal Controls: The company remediated a material weakness in inventory valuation controls identified in 2024. Internal controls over financial reporting were deemed effective as of December 31, 2025.
- Competitive Bidding: The DMEPOS Competitive Bidding Program (CBP) is set to resume in 2026, which could alter reimbursement rates for items like CGMs and insulin pumps.
Investor Verification Checklist
- Goodwill Valuation: Verify the assumptions used in the Diabetes Health impairment test and monitor the "thin margin" of safety in the Wellness at Home and Respiratory Health segments for potential future write-downs.
- Regulatory Impact: Assess the specific impact of the OBBBA on Medicaid enrollment and reimbursement rates once implementation details are finalized for 2027.
- Legal Exposure: Monitor the final court approval of the $35.0 million securities settlement and the outcomes of the two active FCA investigations.
- Debt Covenants: Confirm continued compliance with the Consolidated Total Leverage Ratio and Interest Coverage Ratio covenants under the 2024 Credit Agreement, especially given the recent $100 million revolver drawdown in early 2026.
- Segment Mix: Evaluate the long-term sustainability of the Diabetes Health segment given the payor mix shift and the inclusion of CGMs in the upcoming competitive bidding program.